Search Results for: ezogabine

QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects…

Posted: Published on December 15th, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the results of extensive pre-clinical studies on its lead program, QRA-244, for ALS patients. QRA-244 is a Kv7.2/7.3 ion channel opener optimized for both safety and efficacy as a potential treatment for motor neuron hyperexcitability-induced neurodegeneration in ALS patients Continue reading

Posted in ALS Treatment | Comments Off on QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects…

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related …

Posted: Published on January 8th, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034. SciFluors SF0034 is a potent and selective neuronal potassium channel activator, designed to be a significantly improved version of the first-in-class KCNQ2/3 activator drug, ezogabine (POTIGA). POTIGA was approved in 2011 for treatment of partial-onset epilepsy in adults, but its clinical use was severely restricted in 2013 due to latent toxicities which are not thought to be associated with its mechanism of action. Scott Edwards, Ph.D., Vice President and General Manager, said, The issuance of the patent covering SF0034 provides further validation of our fluorine-centered approach to rapidly discover new transformational therapies for patients with serious illnesses. SF0034 demonstrates how the appropriate fluorine-containing modifications can improve the potency and selectivity of a molecule to address efficacy and safety liabilities. Dr. Edwards is the lead on the SF0034 therapeutic program, which is targeted for development in partial-onset epilepsy and potentially for the recently identified orphan disease, a rare pediatric disorder known as KCNQ2 encephalopathy. The … Continue reading

Comments Off on SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related …

Drugs | BehaveNet

Posted: Published on December 3rd, 2014

- Choose - [1-(5-fluoro-pentyl)-1H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (2R)-amino-5-phosphonopentanoate 1- butyl-3-(1-naphthoyl)indole 1-(1-Phenylcyclohexyl)pyrrolidine 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 1-(5-fluoropentyl)-3-(1-naphthoyl)indole 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole 1-Androstenediol 1-Androstenedione 1-hexyl-3-(1-naphthoyl)indole 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine 1-methyl-4-phenyl-4-propionoxypiperidine 1-pentyl-3-(1-naphthoyl)indole 1-pentyl-3-(2-chlorophenylacetyl)indole 1-pentyl-3-(2-methoxyphenylacetyl)indole 1-pentyl-3-(4-chloro-1-naphthoyl)indole 1-pentyl-3-(4-methoxybenzoyl)indole 1-pentyl-3-(4-methyl-1-naphthoyl)indole 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole 1-Phenylcyclohexylamine 1-Piperidinocyclohexanecarbonitrile 1-[1-(2-Thienyl)cyclohexyl]piperidine 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 1-[2-(4-morpholinyl)ethyl]-3-(1- naphthoyl) indole 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole 10-Hydroxy-carbazepine 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 17Alpha-methyl-4-hydroxynandrolone 17Alpha-methyl-delta1-dihydrotestosterone 19-Nor-4-androstenediol 19-Nor-4-androstenedione 19-Nor-5-androstenediol 19-Nor-5-androstenedione 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 2,5-dimethoxy-4-chlorophenethylamine 2,5-Dimethoxy-4-ethylamphetamine 2,5-dimethoxy-4-ethylphenethylamine 2,5-dimethoxy-4-ethylthiophenethylamine 2,5-dimethoxy-4-iodophenethylamine 2,5-dimethoxy-4-isopropylthiophenethylamine 2,5-Dimethoxy-4-methyl-phenethylamine 2,5-Dimethoxy-4-nitrophenethylamine 2,5-Dimethoxyamphetamine 2,5-dimethoxyphenethylamine 2-(2,5-dimethoxy-4-propylphenyl)ethanamine 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 3,4,5-Trimethoxyamphetamine 3,4-Methylenedioxy-N-ethylamphetamine 3,4-methylenedioxy-N-methylcathinone 3,4-Methylenedioxymethamphetamine 3,4-methylenedioxypyrovalerone 3-Methylfentanyl 3-Methylthiofentanyl 3-Quinuclidinyl benzilate 3Alpha,17beta-dihydroxy-5alpha-androstane 3Beta,17beta-dihydroxy-5alpha-androstane 4 amino 3 hydroxy butyrate 4-Androstenediol 4-Androstenedione 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyphenethylamine 4-bromo-2,5-dimethoxyphenylisopropylamine 4-Dihydrotestosterone 4-fluoromethcathinone 4-Hydroxy-19-nortestosterone 4-Hydroxytestosterone 4-Methyl-2,5-dimethoxyamphetamine 4-Methylaminorex 5-(1,1- dimethylheptyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol 5-Androstenediol 5-Androstenedione 5-Methoxy-3,4-methylenedioxyamphetamine 5-Methoxy-N,N-diisopropyltryptamine 6--naltrexol 7-hydroxymitragynine 8-Chlorotheophylline abecarnil acamprosate acepromazine aceprometazine acetaminophen acetone acetophenazine acetopromazine acetorphine acetyl-alpha-methylfentanyl acetylcarbromal acetylcholine acetyldihydrocodeine acetylmethadol acetylsalicylic acid adinazolam adrafinil adrenochrome agomelatine alfentanil alipazone allylprodine almorexant alpha-ethyltryptamine alpha-Linolenic acid alpha-methylfentanyl alpha-methylthiofentanyl alpha-methyltryptamine alphacetylmethadol (except levo-alphacetylmethadol) alphameprodine alphamethadol alphaprodine alprazolam ALZ-112 ALZ-113 amantadine ambutonium bromide amfonelic acid amiflamine amineptine aminophylline aminorex amisulpride amitriptyline amobarbital amoxapine amperozide amphetamine amyl nitrite anandamide androstenedione anethole anileridine aniracetam apomorphine aprobarbital arecoline aripiprazole armodafinil asarone asenapine aspartic acid atenolol atomoxetine atropine baclofen bananadine barbital befloxatone benactyzine benperidol benserazide bentazepam benzene benzethidine benzoylecgonine benzphetamine benztropine benzylmorphine besipirdine beta endorphin beta-hydroxy-3-methylfentanyl beta-hydroxyfentanyl betacetylmethadol betameprodine betamethadol betaprodine betaxolol bexarotene bezitramide biperiden bolasterone boldenone brallobarbital … Continue reading

Comments Off on Drugs | BehaveNet

Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019

Posted: Published on July 19th, 2014

(PRWEB) July 18, 2014 Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends wrong signals. Seizures could differ from primary generalized seizures to partial seizures depending upon the cause of the epilepsy. Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages. For the treatment of epilepsy, doctors prescribe antiepileptic medicines (AEDs) and the preference for the drug depends on the type of seizures to be treated, age of the patient, part of the brain involved and seriousness of the seizures. On the basis of the available AEDs, epilepsy therapeutics market is segmented into two major categories namely first generation AEDs and second generation AEDs. First generation AEDs consist of following drugs: Get report sample PDF copy from here: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2448. Second generation AEDs consist of medicines with different mechanism of action than the first generation drugs. This segment of epilepsy therapeutics market consists of following drugs: Early buyers will receive 10% customization on this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2448. First generation AEDs majorly … Continue reading

Comments Off on Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019

Research and Markets: Trobalt/Potiga ( Epilepsy ) – Forecast and Market Analysis to 2022 Featuring GSK, UCB, Pfizer …

Posted: Published on March 14th, 2013

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/mvqn44/trobaltpotiga) has announced the addition of GlobalData's new report "Trobalt/Potiga (Epilepsy) - Forecast and Market Analysis to 2022" to their offering. Trobalt/Potiga (Epilepsy) - Forecast and Market Analysis to 2022 Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Trobalt/Potiga (retigabine/ezogabine) is a first-in-class AED that was originally developed by Valeant Pharmaceuticals International and is co-marketed globally with GSK. Although it was originally registered under the molecular name retigabine, in 2010 … Continue reading

Comments Off on Research and Markets: Trobalt/Potiga ( Epilepsy ) – Forecast and Market Analysis to 2022 Featuring GSK, UCB, Pfizer …

The Epilepsy Drug Market Will Increase $800 Million by 2016, Primarily Due to Uptake of Premium-Priced Third …

Posted: Published on December 12th, 2012

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the worlds leading research and advisory firms for pharmaceutical and healthcare issues, finds that the epilepsy market will increase from $2.9 billion in 2011 to nearly $3.7 billion in 2016. The expanding number and growing uptake of third-generation antiepileptic drugs (AEDs), led by lacosamide (UCBs Vimpat) and including other agents such as perampanel (Eisais Fycompa), eslicarbazepine acetate (Sunovion/Bial/Eisais Zebinix/Stedesa*) and ezogabine/retigabine (GlaxoSmithKline/Valeants Potiga/Trobalt), will be a major contributor to such growth. The Pharmacor advisory service entitled Epilepsy also finds that the second-generation AED drug class will maintain its major-market sales-leader position through 2021. Second-generation agents, such as levetiracetam (UCB/Otsuka Pharmaceuticals Keppra/E Keppra, generics; UCBs Keppra XR, generics) and lamotrigine (GlaxoSmithKline/Justes Lamictal, other brands, generics; GlaxoSmithKlines Lamictal XR), continue to displace older, first-generation AEDs across the major-pharmaceutical markets. Notably, agents in this drug class will experience robust uptake in Japan, as many of these drugs have recently launched there, and the U.S. market will see the launch and uptake of extended-release formulations of select members of the drug class, such as SPN-804 (Supernuss Oxtellar XR). At the same time, the use of third-generation AEDs will not supersede that of second-generation drugs, as the former … Continue reading

Comments Off on The Epilepsy Drug Market Will Increase $800 Million by 2016, Primarily Due to Uptake of Premium-Priced Third …